Cannabis Science Inc (OTCMKTS:CBIS) Updates On Progress With Clinical Research And Grow Operations

Preliminary packaging is now being secured and designs are completed for each jurisdiction. Please visit the beta version of the Cannabis Science Patient Access Center (PAC) http://pac.cannabisscience.com for product release information, patient usage tracking, share your usage and support stories with others worldwide, and valuable industry updates. (PRNewsFoto/Cannabis Science, Inc.)

Cannabis Science Inc (OTCMKTS:CBIS) has announced that it would be receiving the first delivery of its pre-designed greenhouses, later this week. The greenhouses are equipped with complete tracking and reporting protocols and would be used for the company’s operations in Nevada and California. CBIS has been rapidly making progress with the development of its grow operations and research facilities. The management has also claimed that they have received a number of inquiries about the availability of treatment options and research.

Preliminary packaging is now being secured and designs are completed for each jurisdiction. Please visit the beta version of the Cannabis Science Patient Access Center (PAC) http://pac.cannabisscience.com for product release information, patient usage tracking, share your usage and support stories with others worldwide, and valuable industry updates. (PRNewsFoto/Cannabis Science, Inc.)

Dr. Allen Herman, the CMO of the company, pointed out that the latest move would provide them with greater control over their supply chain and also improve their efficiencies. He also reassured the shareholders that they are planning to launch observational studies very soon, which would be targeted at critical ailments. Dr. Herman also claimed that a variety of cannabinoid combinations would be grown, by CBIS, for the purpose of formulating and testing.

Regarding customer inquiries, Cannabis Science stated that they have been stored in their database and the company would responding to them individually, once targeted studies commence. The company further stated that the studies would focus over 500 different cannabinoids, which were identified and isolated by Cannabis Sativa. Moreover, the studies would be conducted with the help of CBIS’ consortium of partner universities. The institutions would be responsible for developing protocols for the animal studies and clinical trials, to be conducted concurrently.

Earlier, Cannabis Science announced that its CEO, Raymond C. Dabney and Dr. Herman, would be attended the Global Health Catalyst Summit, due to be held at the Harvard Medical School, on April 28-30, 2017. Each of the two executives has previously visited Harvard, for delivering presentations, which has resulted in the development of synergies between the school and the company.

Cannabis Science Inc (OTCMKTS:CBIS) lost 6.16% of its share value during the March 8 trading session, to close at a share price of $0.0795 per share. The stock had a trade volume of 32.36 million.

 

Cannabis Science Inc (OTCMKTS:CBIS) Updates On Progress With Clinical Research And Grow Operations

more recommended stories

%d bloggers like this: